Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: ABN: Elixinol Wellness Limited 621 479 794 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Date of last notice David Fenlon 03 April 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired + See chapter 19 for defined terms. 01/01/2011 Direct N/A 1) 31 May 2024 2) 31 May 2024 1,250,000 Fully paid Ordinary Shares 465,753 Performance Share Rights 1,250,000 Unlisted Options Fully paid Ordinary Shares Director Fee Rights 1) 2) 11,257,035 Director Fee Rights 3,752,345 Fully paid Ordinary Shares on vesting of Director Fee Rights Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Number disposed 1) 2) Nil 3,752,345 Director Fee Rights converted to Fully Paid Ordinary Shares Value/Consideration 1) Director Fee Rights issued in lieu of cash consideration with a deemed issue price of $0.00533 per Director Fee Right. Nil cash consideration paid on vesting of Director Fee Rights Note: If consideration is non-cash, provide details and estimated valuation 2) No. of securities held after change 5,002,345 Fully paid Ordinary Shares 7,970,443 Performance Share Rights 1,250,000 Unlisted Options Nature of change 1) Issue of Director Fee Rights as approved by Shareholders at the Company’s Annual General Meeting held on 30 May 2024. 2) Issue of Fully paid Ordinary Shares upon vesting of a portion of Director Fee Rights, as approved by Shareholders at the Company’s Annual General Meeting held on 30 May 2024. Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest N/A Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 – +Closed period Were the interests in the securities or contracts detailed No above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided? + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3